Chronic redox imbalance in erythrocytes of individuals with sickle cell disease (SCD) contributes to oxidative stress and likely underlies common etiologies of hemolysis. We measured the amounts of six antioxidant enzymes—SOD1, catalase, glutathione peroxidase 1 (GPx1), as well as peroxiredoxins (Prxs) I, II, and VI—in red blood cells (RBCs) of SCD patients and control subjects. The amounts of SOD1 and Prx VI were reduced by about 17% and 20%, respectively, in SCD RBCs compared with control cells. The amounts of Prx II and GPx1 did not differ between SCD and normal RBCs. However, about 18% of Prx II was inactivated in SCD RBCs as a result of oxidation to sulfinic Prx II, whereas inactive Prx II was virtually undetectable in control cells. Furthermore, GPx1 activity was reduced by about 33% in SCD RBCs, and the loss of activity was correlated with hemolysis in SCD patients. RBCs from SCD patients taking hydroxyurea demonstrated 90% higher GPx1 activity than did those from untreated SCD patients, with no differences seen for the other catalytic antioxidants. Hydroxyurea induced GPx1 expression in multiple cultured cell lines in a manner dependent on both p53 and NO-cGMP signaling pathways. GPx1 expression represents a previously unrecognized potential benefit of hydroxyurea treatment in SCD patients. Antioxid. Redox Signal. 13, 1–11.
AslanM, FreemanBA. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med, 43:1469–1483. 2007.
3.
AslanM, RyanTM, AdlerB, TownesTM, ParksDA, ThompsonJA, ToussonA, GladwinMT, PatelRP, TarpeyMM, Batinic-HaberleI, WhiteCR, FreemanBA. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A, 98:15215–15220. 2001.
4.
BiteauB, LabarreJ, ToledanoMB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature, 425:980–984. 2003.
5.
CharacheS. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol, 34:15–21. 1997.
6.
ChoCS, LeeS, LeeGT, WooHA, ChoiEJ, RheeSG. Irreversible inactivation of glutathione peroxidase 1 and reversible inactivation of peroxiredoxin II by H2O2 in red blood cells. Antioxid Redox Signal, 12:1235–1246. 2010.
7.
CokicVP, SmithRD, Beleslin-CokicBB, NjorogeJM, MillerJL, GladwinMT, SchechterAN. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest, 111:231–239. 2003.
8.
EmburySH, MohandasN, PasztyC, CooperP, CheungAT. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest, 103:915–920. 1999.
9.
EskenaziAE, PinkasJ, WhitinJC, ArguelloF, CohenHJ, FrantzCN. Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. J Natl Cancer Inst, 85:711–721. 1993.
10.
GarelMC, DomengetC, Caburi-MartinJ, PrehuC, GalacterosF, BeuzardY. Covalent binding of glutathione to hemoglobin, I: Inhibition of hemoglobin S polymerization. J Biol Chem, 261:14704–14709. 1986.
GladwinMT, VichinskyE. Pulmonary complications of sickle cell disease. N Engl J Med, 359:2254–2265. 2008.
13.
HebbelRP, MorganWT, EatonJW, HedlundBE. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci U S A, 85:237–241. 1988.
14.
HoYS, MagnenatJL, BronsonRT, CaoJ, GarganoM, SugawaraM, FunkCD. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J Biol Chem, 272:16644–16651. 1997.
15.
HoYS, XiongY, MaW, SpectorA, HoDS. Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J Biol Chem, 279:32804–32812. 2004.
16.
IkutaT, AusendaS, CappelliniMD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci USA, 98:1847–1852. 2001.
17.
JainSK, ShohetSB. A novel phospholipid in irreversibly sickled cells: evidence for in vivo peroxidative membrane damage in sickle cell disease. Blood, 63:362–367. 1984.
18.
JohnsonRM, GoyetteGJr, RavindranathY, HoYS. Hemoglobin autoxidation and regulation of endogenous H2O2 levels in erythrocytes. Free Radic Biol Med, 39:1407–1317. 2005.
19.
JohnsonRM, GoyetteGJr, RavindranathY, HoYS. Oxidation of glutathione peroxidase-deficient red cells by organic peroxides. Blood, 100:1515–1516. 2002.
20.
KatoGJ, GladwinMT. Mechanisms and clinical complications of hemolysis in sickle cell disease and thalassemia. Disorders of Hemoglobin. SteinbergMH, ForgetBG, HiggsDR, WeatherallDJ. Cambridge: Cambridge University Press, 2009; 201–224.
21.
KatoGJ, McGowanV, MachadoRF, LittleJA, TaylorJT, MorrisCR, NicholsJS, WangX, PoljakovicM, MorrisSMJr, GladwinMT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 107:2279–2285. 2006.
22.
KaulDK, HebbelRP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest, 106:411–420. 2000.
23.
KaulDK, LiuXD, ChangHY, NagelRL, FabryME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest, 114:1136–1145. 2004.
24.
KaulDK, LiuXD, ChoongS, BelcherJD, VercellottiGM, HebbelRP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol, 287:H293–H301. 2004.
LeeTH, KimSU, YuSL, KimSH, ParkDS, MoonHB, DhoSH, KwonKS, KwonHJ, HanYH, JeongS, KangSW, ShinHS, LeeKK, RheeSG, YuDY. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood, 101:5033–5038. 2003.
27.
LimJC, ChoiHI, ParkYS, NamHW, WooHA, KwonKS, KimYS, RheeSG, KimK, ChaeHZ. Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. J Biol Chem, 283:28873–28880. 2008.
28.
LiuB, ChenY, St ClairDK. ROS, and p53: a versatile partnership. Free Radic Biol Med, 44:1529–1535. 2008.
29.
LowFM, HamptonMB, PeskinAV, WinterbournCC. Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood, 109:2611–2617. 2007.
30.
MakisAC, HatzimichaelEC, MavridisA, BourantasKL. Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients. Acta Haematol, 104:164–168. 2000.
31.
ManevichY, FisherAB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med, 38:1422–1432. 2005.
MisraHP, FridovichI. The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem, 247:6960–6962. 1972.
34.
MooreRB, MankadMV, ShriverSK, MankadVN, PlishkerGA. Reconstitution of Ca(2+)-dependent K+ transport in erythrocyte membrane vesicles requires a cytoplasmic protein. J Biol Chem, 266:18964–18968. 1991.
35.
MoscowJA, MorrowCS, HeR, MullenbachGT, CowanKH. Structure and function of the 5'-flanking sequence of the human cytosolic selenium-dependent glutathione peroxidase gene (hgpx1)J Biol Chem, 267:5949–5958. 1992.
36.
NagyN, MalikG, FisherAB, DasDK. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol, 291:H2636–H2640. 2006.
37.
NattaCL, ChenLC, ChowCK. Chow. Selenium and glutathione peroxidase levels in sickle cell anemia. Acta Haematol, 83:130–132. 1990.
38.
PigeoletE, CorbisierP, HoubionA, LambertD, MichielsC, RaesM, ZacharyMD, RemacleJ. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev, 51:283–297. 1990.
39.
RadiR, BeckmanJS, BushKM, FreemanBA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys, 288:481–487. 1991.
RepkaT, HebbelRP. Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood, 78:2753–2758. 1991.
42.
RheeSG, ChaeHZ, KimK. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med, 38:1543–1552. 2005.
43.
SchacterL, WarthJA, GordonEM, PrasadA, KleinBL. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J, 2:237–243. 1988.
44.
SebastianiP, NolanVG, BaldwinCT, Abad-GrauMM, WangL, AdewoyeAH, McMahonLC, FarrerLA, TaylorJGT, KatoGJ, GladwinMT, SteinbergMH. A network model to predict the risk of death in sickle cell disease. Blood, 110:2727–2735. 2007.
45.
StaibF, RoblesAI, VarticovskiL, WangXW, ZeebergBR, SirotinM, ZhurkinVB, HofsethLJ, HussainSP, WeinsteinJN, GallePR, HarrisCC. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res, 65:10255–10264. 2005.
46.
SteinbergMH, BartonF, CastroO, PegelowCH, BallasSK, KutlarA, OrringerE, BellevueR, OlivieriN, EckmanJ, VarmaM, RamirezG, AdlerB, SmithW, CarlosT, AtagaK, DeCastroL, BigelowC, SaunthararajahY, TelferM, VichinskyE, ClasterS, ShurinS, BridgesK, WaclawiwM, BondsD, TerrinM. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 289:1645–1651. 2003.
47.
SteinbergMH, NechelesTF. Erythrocyte glutathione peroxidase deficiency: biochemical studies on the mechanisms of drug-induced hemolysis. Am J Med, 50:542–546. 1971.
48.
StraifD, WerzO, KellnerR, BahrU, SteinhilberD. Glutathione peroxidase-1 but not−4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells. Biochem J, 349:455–461. 2000.
49.
VassilevLT. MDM2 inhibitors for cancer therapy. Trends Mol Med, 13:23–31. 2007.
50.
WooHA, JeongW, ChangTS, ParkKJ, ParkSJ, YangJS, RheeSG. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem, 280:3125–3128. 2005.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
